Trial Information
Prospective, Multicentre, Non-interventional (Observational) Study of VANTAS® for the Treatment of Patients With Advanced Prostate Cancer.
Inclusion Criteria:
- Male patients for whom hormone treatment for advanced prostate cancer is indicated
- Age > 18 years.
- Documented elevated PSA levels.
Exclusion Criteria:
Contraindications for Vantas® (in accordance with Summary of Product Characteristics
(SmPC))
Type of Study:
Observational
Study Design:
Observational Model: Case-Only, Time Perspective: Prospective
Outcome Measure:
Treatment duration follow-up for each patient.
Outcome Time Frame:
1 year
Safety Issue:
No
Principal Investigator
Thomas Björk, MD
Investigator Role:
Principal Investigator
Investigator Affiliation:
Urology Dep. Skane University Hospital, Malmoe, Sweden
Authority:
Sweden: Regional Ethical Review Board
Study ID:
THE VANTAS STUDY
NCT ID:
NCT01574846
Start Date:
January 2011
Completion Date:
June 2014
Related Keywords:
- Prostate Cancer
- Prostatic Neoplasms